IMD 2329
Alternative Names: IMD-2329Latest Information Update: 12 Jul 2024
At a glance
- Originator Shanghai Affinity Biopharmaceutical
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Jul 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to July 2024 (Shanghai Affinity Biopharmaceutical pipeline, July 2024)